KEAP1 genetic polymorphisms associate with breast cancer risk and survival outcomes

Clinical Cancer Research

Volumn 21, Issue 7, 2015, Pages 1591-1601

  Hartikainen, Jaana M ^a   Tengström, Maria ^a,b   Winqvist, Robert ^c,d   Jukkola Vuorinen, Arja ^c   Pylkäs, Katri ^c,d   Kosma, Veli Matti ^a,b   Soini, Ylermi ^a,b   Mannermaa, Arto ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d Laboratory of Cancer Genetics and Tumor Biology   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TAMOXIFEN; TRANSCRIPTION FACTOR NRF2; KEAP1 PROTEIN, HUMAN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIGNAL PEPTIDE;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CONTROLLED STUDY; FEMALE; FINN (CITIZEN); GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR INVASION; BREAST NEOPLASMS; CASE CONTROL STUDY; CHILD; DNA MICROARRAY; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RADIOTHERAPY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIOTHERAPY; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84927595662     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1887     Document Type: Article

References (50)

1. Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med (Berl) 1996;74:297-312. Erratum in: J Mol Med 1997;75:67-8.
2. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010;49:1603-16.
3. Niture SK, Khatri R, Jaiswal AK. Regulation of Nrf2-an update. Free Radic Biol Med 2014;66:36-44.
4. Sun Z, Zhang S, Chan JY, Zhang DD. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol Cell Biol 2007;27:6334-49.
5. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011;20:524-37.
6. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, et al. Direct interaction between Nrf2 and p21(Cip/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 2009;34:663-73.
7. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap 1 and p62. Mol Cell Biol 2010;30:3275-85.
8. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010;12:213-23.
9. Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA, et al. Wilms tumor gene on the X chromosome (WTX) inhibits the degradation of NRF2 through competitive binding to KEAP1. J Biol Chem 2012;287:6539-50.
10. Kim WD, Kim YW, Cho IJ, Lee CH, Kim SG. E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells. J Cell Sci 2012;125:1284-95.
11. Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, et al. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol 2012;32:1506-17.
12. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34:176-88.
13. Hu L, Miao W, Loignon M, Kandouz M, Batist G. Putative chemopreventive molecules can increase Nrf2-regulated cell defence in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemoter Pharmacol 2010;66:467-74.
14. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
15. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-9.
16. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010;220:446-51.
17. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013;45:860-7.
18. Yoo NJ, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 2012;60:943-52.
19. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast cancer. Nature 2012;490:61-70.
20. Tavassoli FA, Devilee P. Tumours of the breast and female genital organs. World Health Organization classification of tumours. Lyon, France: IARC Press; 2003.
21. Karihtala P, Kauppila S, Puistola U, Jukkola-Vuorinen A. Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology 2011;58:854-62.
22. Okoh V, Deoraj A, Roy D. Estrogen-induced reactive oxygen species-mediated signaling contribute to breast cancer. Biochim Biophys Acta 2011;1815:115-33.
23. Hartikainen JM, Tengström M, Kosma V-M, Kinnula VL, Mannermaa A, Soini Y. Genetic polymorphisms and protein expression of NRF2 and sulfiredoxin predict survival outcomes in breast cancer. Cancer Res 2012;72:5537-46.
24. Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, et al. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQO1, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1784-94.
25. Wong TF, Yoshinaga K, Monma Y, Ito K, Niikura H, Nagase S, et al. Association of Keap1 and Nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival. Int J Gynecol Cancer 2011;21:1428-35.
26. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010;16:3743-53.
27. Singh A, Ling G, Shasini AN, Zhang P, Yamamoto M, Navas-Acien A, et al. Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs. Free Radic Biol Med 2009;46:376-86.
28. Kauppinen JM, Kosma V-M, Soini Y, Sironen R, Nissinen M, Nykopp TK, et al. ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival. Cancer Epidemiology Biomarkers Prev 2010;19:2133-42.
29. Solyom S, Aressy B, Pylkäs K, Patterson-Fortin J, Hartikainen JM, Kallioniemi A, et al. Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med 2012;4:122rs23.
30. Vandenplas S, Wiid J, Grobler-Rabie A, Brebner K, Ricketts M, Wållis G, et al. Blot hybridization of genomic DNA. J Med Genet 1984;21:164-72.
31. International HapMap Project. [cited 2010 Feb 24]. Available from: http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap3r2-B36/.
32. Institute for Human Genetics. [cited 2014 Nov 1]. Available from: http://ihg.gsf.de/cgi-bin/hw/hwa2.pl.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc Ser B (Methodological) 1995;57:289-300. doi:10.2307/2346101.
34. UCSC Genome Bioinformatics. [Human Feb. 2009 genome GRCh37/hg19 assembly, cited 2014 May 9]. Available from: http://genome.ucsc.edu/.
35. Ensembl. [cited 2014 May 9]. Available from: www.ensembl.org.
36. Lo S-C, Li X, Henzl MT, Beamer LJ, Hannik M. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J 2006;25:3605-17.
37. 1000 Genomes. [cited 2014 May 9]. Available from: www.1000genomes.org.
38. Eades G, Yang M, Yao Y, Zhang Y, Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem 2011;286:40725-33.
39. TargetScan. [cited 2014 May 9]. Available from: www.targetscan.org.
40. microRNA.org. [cited 2014 May 9]. Available from: www.microrna.org.
41. Montano MM, Chaplin LJ, Deng H, Mesia-Vela S, Gaigwad N, Zahid M, et al. Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis. Oncogene 2007;26:3587-90.
42. Sripathy SP, Chaplin LJ, Gaikwad NW, Rogan EG, Montano MM. hPMC2 is required for recruiting an ERb coactivator complex to mediate transcriptional upregulation of NGO1 and protection against oxidative DNA damage by tamoxifen. Oncogene 2008;27:6376-84.
43. Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 1999;79:257-63.
44. Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 2007;67:1282-90.
45. Wozniak K, Kolacinska A, Blasinska-Morawiec M, Morawiec-Bajda A, Morawiec Z, Zadrozny M, et al. The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol 2007;81:519-27.
46. Yao Y, Brodie AMH, Davidson NE, Kensler TW, Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat 2010;124:585-91.
47. Cook KL, Clarke PAG, Parmar J, Hu R, Schwarz-Roberts JL, Abu-Asab M, et al. Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death. FASEB J. 2014 May 23. - [Epub ahead of print].
48. van Jaarsveld MTM, Helleman J, Boersma AWM, van Kuijk PF, van Ijcken WF, Despierre E, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013;32:4284-93.
49. Wang J, Zhuang J, Iyer S, Lin X, Whitfield TW, Greven MC, et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res. 2012;22:1798-812.
50. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994;65:27-33.